Singapore, July 9 -- Australian biotech Aegros has completed Australia's second human plasma fractionation facility, joining CSL's long-established footprint. The 4000 sq mt Macquarie Park facility will utilise Aegros's manufacturing technology Haemafrac(R).

The process offers a higher protein production efficiency and increased cost benefit, improving upon still commonly used decades old technology.

Aegros's facility has the initial capacity to process up to 125,000 litres of human plasma, producing hyperimmune globulins and immunoglobulin, plasma proteins to treat immune deficiencies, neurological disorders and as transplant anti-rejection therapy.

Aegros has designed its plant to eventually process up to 250,000 litres to meet the d...